Spotlight

University of Exeter tackles the overlooked fungal disease crisis

As fungal infections claim millions of lives worldwide, the University of Exeter is expanding its international research network to improve diagnosis, treatment and disease surveillance.

17 November 2026

Fungal infections remain a largely overlooked global health threat, with millions of lives at risk each year from diseases that are often difficult to diagnose and treat. To address this challenge, the University of Exeter has partnered with Mahidol University in Thailand to establish a new medical mycology research unit in Bangkok, strengthening its existing network across Africa and Latin America.

QS Insights sat down with Professor Adilia Warris, Co-Director of the MRC Centre for Medical Mycology at the University of Exeter, to discuss how international research collaboration can improve fungal disease surveillance, accelerate diagnosis and treatment, and build lasting clinical expertise in Southeast Asia.

QS: An estimated 3.8 million deaths worldwide each year are associated with fungal infections, yet fungal disease remains underdiagnosed and under-resourced. Why has this health threat received comparatively little attention, and where can university-led research make the greatest difference?

Professor Adilia Warris: The short answer is that the threat has grown faster than awareness, research investment and clinical capacity. We saw a major increase in fungal infections during the AIDS epidemic in the 1980s. Since then, advances in cancer treatment, transplantation and intensive care have meant that more people are living with weakened immune systems and are therefore vulnerable to fungal infections. At the same time, the growing use of antifungal medicines has contributed to drug resistance. The population at risk has grown rapidly, but the specialist workforce and clinical capacity needed to respond have not kept pace.

Collaborative research is essential to improve our understanding of fungal biology, develop new diagnostics and treatments, and address emerging global challenges such as antifungal resistance. At the MRC Centre for Medical Mycology at the University of Exeter, we combine fundamental science and clinical research with international partnerships capable of translating discoveries into improvements in patient care.

Global partnerships are especially important here because the disease burden, the pathogens involved and the barriers to care vary considerably between regions.

QS: Southeast Asia faces particular challenges from fungal diseases such as talaromycosis and fungal keratitis. How will Exeter and Mahidol University decide which regional health needs to prioritise, and how will local clinical expertise shape the unit’s research agenda?

AW: The greatest burden of serious fungal infections falls on low-and middle-income countries, where access to diagnostics, treatments and specialist training can be limited.

Asia is home to more than half of the world’s population and bears a large share of the estimated 6.5 million life-threatening fungal infections and 3.8 million deaths that occur globally each year. The region combines a growing population of people with a greater risk of infection, including patients with advanced HIV disease (AHD), tuberculosis, diabetes, cancer, as well as transplant recipients and others with weakened immune systems, with a hot, humid climate, extreme weather and extensive agricultural azole use. Research priorities will therefore be agreed with regional researchers, clinicians and public-health partners, drawing on local surveillance data, clinical experience and evidence about where the Unit can make the greatest difference. This will include regionally significant diseases such as talaromycosis and fungal keratitis, where local clinicians have identified substantial unmet needs in diagnosis, treatment or prevention.

The CMM Southeast Asia Unit, recently launched in Bangkok through a partnership between the universities of Exeter and Mahidol, will strengthen fungal surveillance and outbreak preparedness, deploy rapid point-of-care diagnostics and conduct clinical trials involving patients in Southeast Asia and focused on the fungal pathogens most prevalent in the region. The new Unit will also support epidemiological and translational research and develop the next generation of Southeast Asian mycologists.

QS: The unit plans to strengthen fungal disease surveillance and introduce rapid point-of-care diagnostics. What are the most pressing gaps in detecting fungal infections across the region, and how could improved diagnosis change treatment and patient outcomes?

AW: The central problem is that fungal infections are often not considered early enough, and many hospitals do not have access to rapid, affordable tests. Their symptoms can resemble tuberculosis, bacterial infection or other diseases, so patients may receive the wrong treatment while the fungal infection progresses.

The consequences of these diagnostic gaps can be severe. Talaromycosis causes approximately 17,000 cases and 5,000 deaths annually and kills up to one-third of patients despite treatment. Mucormycosis incidence in India is up to 70 times higher than elsewhere, driven by uncontrolled diabetes and corticosteroid use. Fungal keratitis affects more than one million people each year, nearly 90% of them in Asia, with Fusarium as the leading cause and agricultural workers particularly at risk of blindness. Chronic pulmonary aspergillosis complicates recovery from tuberculosis, yet remains underdiagnosed. Across these diseases, limited access to diagnostics and susceptibility testing means that infections are often identified late or mistaken for other conditions, delaying appropriate treatment.

But these challenges also present opportunities for major impact. One of the Unit’s key areas of focus will be developing and implementing affordable rapid diagnostics and fungal screening approaches tailored to resource-limited healthcare settings.

The Unit will also work to evaluate how well these screening strategies work in practice, how cost-effective they are, and how they can be scaled up across the region.

Developing these tests is not straightforward. Some fungal pathogens are difficult to grow using conventional laboratory methods, while others must be distinguished from closely related fungi that live harmlessly in the environment. By bringing together specialist scientific expertise and regional clinical knowledge, the Unit will be better placed to develop tests that are scientifically reliable and workable in the hospitals where they are needed.

Earlier and more accurate diagnosis would allow clinicians to begin the right treatment sooner, avoid unnecessary antibacterial treatment and reduce preventable deaths, disability and blindness.

QS: Antifungal drug resistance is making some infections increasingly difficult to treat. How will the Southeast Asia Unit investigate this challenge, including through clinical trials, and what will be needed to translate research findings into treatments that patients can access?

AW: Coordinated surveillance and reporting will be essential. By gathering comparable data across countries and monitoring how resistance changes over time, we can identify emerging threats, understand which treatments are becoming less effective and focus research where it is most needed.

Antifungal resistance is rising rapidly: fluconazole resistance in Candida tropicalis in China rose from 6% to 32% within nine years, environmental azole-resistant Aspergillus fumigatus is widespread in Vietnam, and Trichophyton indotineae, which causes a drug-resistant skin infection, has spread from India worldwide.

We already know that environmental fungi in Southeast Asia contain significant reservoirs of genes associated with antifungal resistance, and we need to remain alert to the emergence of new resistant strains or species.

Fungal surveillance, antifungal resistance and outbreak preparedness will be a primary focus for the new Southeast Asia Unit. The Unit will establish coordinated monitoring of fungal disease and antifungal resistance across its network sites. This will include adapting AMASS, the AutoMated tool for Antimicrobial Resistance Surveillance System developed by colleagues at Mahidol University, which is already used for bacterial bloodstream infections, to incorporate fungal pathogens. It will also help add fungal pathogens to the World Health Organisation-supported national Antimicrobial Resistance (AMR) surveillance networks, including those reporting to the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS). Building on its Candida bloodstream infections (GLASS-FUNGI), so that fungal resistance data become part of routine national and global reporting.

Improved surveillance data will help the Unit design clinical trials around the fungal pathogens, patient populations and treatment constraints found in Southeast Asia. Working through hospitals across the regional network will allow researchers to test whether new treatments, or new uses of existing treatments, are effective in real clinical settings.

A successful trial is only one step towards patient access. Researchers will also need to work with health ministries, regulators, healthcare providers and industry so that effective treatments can be approved, incorporated into clinical guidance, procured affordably and supplied reliably. Cost, storage, ease of administration and suitability for local health systems will therefore need to be considered from the outset.

QS: Exeter’s medical mycology network already includes units in Cape Town and São Paulo. What lessons from these partnerships are informing the Bangkok unit, and how will the three regional centres share knowledge while pursuing research priorities specific to their populations?

AW: The epidemiology of fungal disease varies considerably between and within regions, as does access to specialist expertise, diagnostics and medicines. Capacity building and the development of new diagnostic and treatment approaches must therefore reflect local disease burdens and healthcare systems. At the same time, learning from regional teams needs to be shared internationally. Greater global capacity and collaboration in medical mycology will be essential as we respond to rising threats including climate change and antifungal resistance.

Our experience in Africa and Latin America has taught us that successful international units must be locally led, focused on the diseases that matter most in their regions and built for the long term. Research, training and clinical capacity development must reinforce one another and create a sustainable base for regional leadership.

The CMM AFRICA Unit, established at the University of Cape Town in 2017, facilitates research and training in South Africa and across the wider continent. Its research programme focuses on regionally significant fungal diseases, including cryptococcal meningitis, emergomycosis and pneumocystis pneumonia.

The CMM LATAM Unit, established at the University of São Paulo in 2024, has already supported 13 research projects across Latin America and invested in mobility and international collaboration through five further projects. Together, these activities represent an investment of £1.15 million, supported by the MRC Centre for Medical Mycology at the University of Exeter, FAPESP, FAILSAFE and Fiocruz. Its work addresses endemic fungal diseases including sporotrichosis and histoplasmosis.

The CMM Southeast Asia Unit will build on these lessons through mentorship, fellowships, collaborative research and support for competitive funding, enabling Southeast Asian scientists to lead solutions to regional problems. It will be connected with the CMM at Exeter and the units in Cape Town and São Paulo, creating an integrated global network for sharing research methods, training models and emerging findings.

Each regional unit will retain a distinct agenda shaped by its populations, disease burden and health systems, while contributing its expertise and evidence to joint work on global challenges. This gives the network cohesion without imposing a single research programme on regions with very different needs.

QS: Training the next generation of Southeast Asian mycologists is a central aim of the new unit. How will Exeter and its partners build sustainable local research and clinical capacity, and what concrete changes would demonstrate the network’s success over the next five years?

AW: Training the trainers and building sustainable regional capacity may ultimately be the most important contribution we can make as a global community of researchers and clinicians. Over the next five years and beyond, the network aims to advance fungal disease research, develop practical solutions and improve patient care around the world.

Underpinning these objectives is our commitment to structured training in clinical and laboratory mycology, research methods and trial conduct for local scientists, clinicians and researchers, empowering them to address the issues most highly relevant to their region.

Researchers and clinicians across Southeast Asia will have access to CMM-, FAILSAFE- and Pasteur Institute-sponsored courses and workshops, strengthening regional expertise in fungal diagnosis. In partnership with the US CDC Mycology Branch, we will also provide on-site mycology training for leading clinical laboratories in participating countries, which can then act as national reference centres and cascade skills to other hospitals.

Over the next five years, success would mean more laboratories able to diagnose fungal infections accurately; national reference centres training and supporting other hospitals; more Southeast Asian researchers leading internationally competitive studies and clinical trials; stronger regional surveillance data; and new diagnostic approaches being adopted in routine care. Ultimately, we would want to see evidence of earlier diagnosis, more appropriate treatment and better outcomes for patients.

Together, the CMM and its three regional units will provide a sustained structure through which researchers and clinicians can share expertise, methods and evidence across regions.